OUR TOOLS
Explore the variety of ways your team can gain insight using our methodologies.
Client-Tailored Solutions
We have tools to inform whatever R&D decisions you’re facing in any stage of development, including: advising on go/no-go decisions, evaluating BD opportunities, share forecasting, patient flow modeling, assessing market access, and setting indication priorities. We can help you find the answers you need.
Our Offerings
Disease Area Scan (DAS)
Compare key criteria across candidate indications such as each population’s unmet medical need, size, and competitive intensity.
We use heat maps to convey what levels of improvement in efficacy and safety will correspond to certain levels of clinical innovation and patient share potential in each indication.
- Unmet need analysis under the current standard of care in each indication to understand where the whitespace exists
- Heat maps, detailing how varying efficacy and safety profiles can be expected to perform commercially in each indication
- Project-level data visualization to assist strategy decisions
- 2 years free after-sales support from kickoff
Disease Target Assessment (DTA)
DTA models predict peak patient share for any modeled TPP and can instantly be updated when new data emerges.
We achieve this by calculating Clinical Innovation, which is the percent reduction in unmet medical need an agent delivers compared with the standard of care.
- Everything in Disease Area Scan
- Dynamic Excel model with scenario-planning capabilities and instant updates when inputs are changed
- Peak-year patient share projections for your asset in each population
- Drivers of Clinical Innovation graphics, which communicate how your TPP is differentiated in efficacy, safety, convenience, drug cost, as well as impacts on mortality, morbidity, and non-drug costs inflicted by the disease
- Competitive pipeline assessment
- Detailed, head-to-head comparisons between all modeled entrants in the market
- Market Access view to assess the appropriateness of your price based on historical analogs
- 5-10 KOL interviews with detailed analysis
Dynamic Patient Share Forecasting
The forecast functionality of the “Competition Module” takes into account the clinical attributes of the user’s TPP along with that of its competitors and each asset’s launch timing in order to forecast quarterly share and provide insight into how different agents will compete with each other in the market.
- Everything in Disease Target Assessment
- Dynamic Excel-based patient share forecast built into DTA model which predicts quarterly share across all agents in the market
- Predicts impacts of order of entry and launch timing
- Simulation and Monte Carlo capabilities, if needed
Dynamic Patient Flow Modeling and Epidemiology
- Bespoke incidence-based patient-flow models and epidemiology forecasts
- Accurately estimates the number of patients available for treatment at each stage of disease and line of treatment
- Projects how evolution in treatment landscapes will impact the number of addressable patients
The Foundation of our Analyses
The “Disease Target Assessment” (DTA) model, which is the go-to tool for our clients, acts as the foundation of all of our forecast models. The DTA model aims to quantify the level of unmet medical need in a given indication under the current standard of care. Emerging agents are measured against this benchmark based on the reduction in unmet medical need that they offer. This methodology is adapted and expanded upon in order to fit each client’s unique needs in disease-are strategy, business development, early R&D, late-stage development, and beyond. The primary output of the DTA is an assets projected peak-year patient share.
Explore the Offerings More Closely
